Indications for liraglutide injection pen

It is indicated for the control of blood glucose in adults with type 2 diabetes mellitus:

1. For patients with poor glycaemic control despite treatment with the maximum tolerable dose of metformin or sulphonylurea alone, in combination with metformin or sulphonylurea.

2. Indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adult patients with type 2 diabetes mellitus with cardiovascular disease.

It is indicated as an adjunct to a low-calorie diet and increased exercise in adult patients requiring long-term weight management:

1. Adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese)

2. ≥27kg/m2 (overweight) with at least one weight-related comorbidity (e.g. hypertension, type 2 diabetes mellitus or dyslipidaemia)

Dosage of liraglutide injection pen

Usage:

This product can be injected once a day, at any time of the day or night, and does not need to be given according to meal times. The product is administered by subcutaneous injection at a site of choice in the abdomen, thigh or upper arm. No dose adjustment is required when changing the site and time of injection. However, it is recommended that this product be injected at the same time each day and the most convenient time of day should be chosen. This product should not be given intravenously or intramuscularly. Dosage:

Glucose control in adults with type 2 diabetes:

To improve gastrointestinal tolerance, the starting dose of liraglutide is 0.6 mg per day. After at least 1 week, the dose should be increased to 1.2 mg. It is expected that some patients may benefit from increasing the dose from 1.2 mg to 1.8 mg, and depending on the clinical response, the dose may be increased to 1.8 mg after at least one week in order to further improve the glucose-lowering effect. Rcommended daily dose does not exceed 1.8 mg.

This product can be used in combination therapy with metformin without changing the dose of metformin.

This product may be used in combination therapy with sulfonylureas. When this product is used in combination with a sulphonylurea, consideration should be given to reducing the dose of the sulphonylurea to reduce the risk of hypoglycaemia.

Blood glucose monitoring is not required when the dose of this product is adjusted. However, blood glucose monitoring may be required when the dose of a sulfonylurea is adjusted as a result of combination therapy of this product with a sulfonylurea.

Precautions for using liraglutide injection pen

Treatment is accompanied by transient adverse gastrointestinal reactions, including nausea, vomiting and diarrhoea. Usually reduces gradually after 2-3 days of medication.

A few cases of acute pancreatitis have been reported. Patients should be aware of the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain. If pancreatitis is suspected, you should discontinue and other potentially suspicious medications and seek prompt medical attention.

Patients treated with liraglutide in combination with sulfonylureas may be at increased risk of hypoglycaemia. Reducing the dose of sulfonylureas may reduce the risk of hypoglycaemia.

Storage of liraglutide injection pen

This product does not contain an injection needle. It should be used with Novo needles up to 8mm long and up to 32G fine. Use only when colourless and clear. This product should be refrigerated in a refrigerator at 2°C - 8°C (do not approach the freezer compartment of the refrigerator). It should not be frozen. After first use, it should be stored below 30°C or refrigerated in a 2°C-8°C refrigerator with the pen cap on to protect it from light. The expiry date after first use is 1 month. Do not store the refill of this product with a needle.

The information is from the Internet and is for reference only.